questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases
Signalisation cellulaire
Protéomique
Phosphorylation
Cancers
Maladies inflammatoires
Symptômes
5
Système immunitaire
Réponse immunitaire
Éruptions cutanées
Troubles métaboliques
Troubles neurologiques
Dysfonction
Stress cellulaire
Apoptose
Prévention
5
Mode de vie sain
Nutrition
Tabagisme
Graisses saturées
Traitements
5
Thérapie génique
Mutations
Médicaments
Inhibiteurs de MEK
Plantes médicinales
Signalisation
Complications
5
Complications
Inflammation chronique
Maladies auto-immunes
Anomalies
Cancer
Activation aberrante
Risques cardiovasculaires
Maladies cardiovasculaires
Vieillissement
Dysfonctionnements
Facteurs de risque
5
Âge
Signalisation cellulaire
Prédispositions génétiques
Mutations
Mode de vie sédentaire
Mauvaise alimentation
Infections virales
Perturbation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes",
"headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Extracellular Signal-Regulated MAP Kinases",
"url": "https://questionsmedicales.fr/mesh/D048049",
"about": {
"@type": "MedicalCondition",
"name": "Extracellular Signal-Regulated MAP Kinases",
"code": {
"@type": "MedicalCode",
"code": "D048049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3",
"alternateName": "Mitogen-Activated Protein Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048052",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Wang",
"url": "https://questionsmedicales.fr/author/Juan%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Mohammad Shafiq",
"url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Kumaravelu Jagavelu",
"url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Neeraj Kumar Verma",
"url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Jimut Kanti Ghosh",
"url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Public Health Impact of FDA's Request for Additional Safety Data on Cytisine for Tobacco Cessation.",
"datePublished": "2024-08-02",
"url": "https://questionsmedicales.fr/article/39177985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamahealthforum.2024.2647"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial.",
"datePublished": "2022-07-28",
"url": "https://questionsmedicales.fr/article/35908731",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtho.2022.07.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety and efficacy of CyTisine for smoking cessation in a hOSPital context (CITOSP): study protocol for a prospective observational study.",
"datePublished": "2024-09-30",
"url": "https://questionsmedicales.fr/article/39403432",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2024.1350176"
}
},
{
"@type": "ScholarlyArticle",
"name": "The efficacy and acceptability of pharmacological monotherapies and e-cigarette on smoking cessation: a systemic review and network meta-analysis.",
"datePublished": "2024-05-22",
"url": "https://questionsmedicales.fr/article/38841681",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2024.1361186"
}
},
{
"@type": "ScholarlyArticle",
"name": "Synthesis of the Key Intermediate of SM-406 (Xevinapant) and Its Analogues.",
"datePublished": "2022-09-15",
"url": "https://questionsmedicales.fr/article/36107820",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.joc.2c01173"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D020928"
},
{
"@type": "ListItem",
"position": 7,
"name": "Extracellular Signal-Regulated MAP Kinases",
"item": "https://questionsmedicales.fr/mesh/D048049"
},
{
"@type": "ListItem",
"position": 8,
"name": "Mitogen-Activated Protein Kinase 3",
"item": "https://questionsmedicales.fr/mesh/D048052"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3",
"description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Azocines#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitogen-Activated Protein Kinase 3",
"description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Azocines#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitogen-Activated Protein Kinase 3",
"description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Azocines#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitogen-Activated Protein Kinase 3",
"description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Azocines#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitogen-Activated Protein Kinase 3",
"description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Azocines#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3",
"description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Azocines#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de MAPK3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer MAPK3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de phosphorylation et les analyses protéomiques sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à MAPK3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est liée à des cancers et des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner une inflammation et des douleurs."
}
},
{
"@type": "Question",
"name": "MAPK3 affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à MAPK3 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de MAPK3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour MAPK3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter MAPK3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Des exercices spécifiques aident-ils MAPK3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3."
}
},
{
"@type": "Question",
"name": "La gestion du poids influence-t-elle MAPK3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent MAPK3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle corriger MAPK3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent la voie MAPK3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour MAPK3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle MAPK3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle liée à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment MAPK3 affecte-t-elle le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "MAPK3 peut-elle influencer le vieillissement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à MAPK3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'activité de MAPK3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il MAPK3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles affecter MAPK3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber la signalisation de MAPK3."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 18/02/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India.
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India.
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Institute for Zellbiochemie, Medizinische Hochschule Hannover (MHH), Hanover, Germany (M.G.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India.
Academy of Scientific and Innovative Research, Ghaziabad, India (M.S., K.J., K.H.).
Publications dans "Mitogen-Activated Protein Kinase 3" :
2 publications dans cette catégorie
Affiliations :
Department of Radiology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Department of Life Science (BK21 program), Chung-Ang University, Seoul, South Korea.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. tayebmuhammad@nwsuaf.edu.cn.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. tayebmuhammad@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. 15591858981@163.com.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. 15591858981@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. 15891785931@163.com.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. 15891785931@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. liyushunaf@163.com.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. liyushunaf@163.com.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. feizhang@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. zhangyan2014@nwsuaf.edu.cn.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. zhangyan2014@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
College of Horticulture, Northwest A&F University, Yangling 712100, China. liangyan@nwsuaf.edu.cn.
State Key Laboratory of Crop Stress Biology in Arid Regions, Northwest A&F University, Yangling 712100, China. liangyan@nwsuaf.edu.cn.
Publications dans "Mitogen-Activated Protein Kinase 3" :
1 publication dans cette catégorie
Affiliations :
Division of Gastroenterology, Department of Medicine Jichi Medical University School of Medicine Shimotsuke Tochigi Japan.
Publications dans "Mitogen-Activated Protein Kinase 3" :
No new tobacco cessation medication has been licensed in the US since 2006. Cytisine, a plant-based partial agonist of nicotinic acetylcholine receptors, has demonstrated safety and efficacy in severa...
To project the potential public health impact of cytisine, and delays in its availability, as a smoking cessation aid in the US....
This mathematical model estimated life expectancy gains from smoking cessation for people aged 18 to 99 years in the US, reflecting the civilian, noninstitutionalized population. The model also accoun...
Cytisine availability as a tobacco cessation treatment immediately or after 1 year....
The main outcomes were the number of adults able to stop smoking and sustain long-term abstinence and aggregate life-years gained....
The base case includes an estimated 29.4 million US civilian noninstitutionalized adults who smoke cigarettes (age distribution, 18-24 years: 5.5%; 25-44 years: 37.3%; 45-64 years: 41.8%; ≥65 years: 1...
Smoking cessation generates large gains in life expectancy. This mathematical model demonstrated that immediate cytisine availability, even if used successfully by only a small fraction of people who ...
Cytisine, a partial agonist-binding nicotine acetylcholine receptor, is a promising cessation intervention. We conducted a single-center, randomized, controlled trial (RCT) in Italy to assess the effi...
From July 2019 to March 2020, the Screening and Multiple Intervention on Lung Epidemics RCT enrolled 869 current heavy tobacco users in a low-dose computed tomography screening program, with a randomi...
At the 12-month follow-up, the quit rate was 32.1% (151 participants) in the intervention arm and 7.3% (29 participants) in the control arm. The adjusted OR of continuous abstinence was 7.2 (95% confi...
The efficacy and safety observed in the Screening and Multiple Intervention on Lung Epidemics RCT indicate that cytisine, a very low-cost medication, is a useful treatment option for smoking cessation...
Tobacco addiction is the primary preventable factor contributing to global mortality, and nicotine is one of the substances with the greatest potential for addiction. With a strong affinity for the α4...
Several pharmacological interventions, such as nicotine replacement therapy (NRT), varenicline, and bupropion, have been approved for clinical use of smoking cessation. E-cigarettes (EC) are increasin...
This systematic review and NMA searched all clinical studies on smoking cessation using pharmacological monotherapies or e-cigarettes published from January 2011 to May 2022 using MEDLINE, COCHRANE Li...
The final 40 clinical studies included in this study comprised 77 study cohorts and 25,889 participants. Varenicline is more effective intervention to assist in smoking cessation during 16-32 weeks fo...
This review suggested and agreed that Varenicline, Cytisine and transdermal nicotine delivery, as smoking cessation intervention, have advantages and disadvantages. However, we had to have reservation...
Efficient methods for the synthesis of three dipeptide mimetics with diazabicycloalkanone amino acid scaffolds were developed. Among them, compound...
Cytisine is a smoking cessation medication. This systematic review incorporates recently published randomized controlled trials (RCTs) to provide an updated evidence-based assessment of cytisine's eff...
We searched Cochrane Library, MEDLINE, and EMBASE, for RCTs comparing cytisine to other smoking cessation treatments in adults who smoke....
6-month biochemically verified continuous abstinence. Other outcomes: abstinence at longest follow-up, adverse events, mortality, and health-related quality of life (HRQOL). We used Grading of Recomme...
We included 14 RCTs involving 9953 adults. Cytisine was superior to placebo (risk ratio [RR] 2.25, 95% confidence interval [CI] 1.13-4.47; 5 RCTs, 4325 participants), but not varenicline (RR 1.13, 95%...
Cytisine shows greater efficacy than placebo and NRT, but more adverse events. It is comparable to varenicline, with fewer adverse events. This can inform clinicians and guidelines on cytisine for smo...
Much attention has been paid to the environmental toxicity and ecological risk caused by cyclic tetramethylene tetranitramine (HMX) pollution in military activity sites. In this study, the response me...
Aberrant signaling of EGFR (ErbB) family members, in particular epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2), is associated with the occurrence and development of...
Cytisine is considered to be the oldest medication for smoking cessation and has been used for this purpose in some Eastern/Central European and Central Asian countries for over 50 years. Several sour...
Safety concerns remain a bottleneck for the application of 2,4,6,8,10,12-hexanitro- 2,4,6,8,10,12-hexaazaisowurtzitane (CL-20)/1,3,5,7-tetranitro-1,3,5,7-tetrazacyclooctane (HMX) cocrystal. Melamine-f...